Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology
-$0.03 today
- Market cap
- $109.26M
- Beta
- 0.74
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.37
Volume 2.90M
Average 7.64M
CMPX Total Non-current Liabilities
All obligations due after more than one year.
Compass Therapeutics, Inc.NASDAQ: CMPX
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 34.2% from a year ago
Total non-current liabilities stood at $8.42M at the end of Q1 FY2026, up 34.2% from a year earlier and down 4.7% from the prior quarter. Over 3 fiscal years it compounded at +68.7% a year.
Context
- Total non-current liabilities amounted to 4.1% of total assets at the end of Q1 FY2026, down 0.7 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +34.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 8.83M USD
- Year-over-year change
- +40.2%
- 4-year CAGR
- +30.5%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.83M | +40.2% |
| FY2024 | 2024-12-31 | 6.3M | +1074.8% |
| FY2023 | 2023-12-31 | 536K | -70.8% |
| FY2022 | 2022-12-31 | 1.84M | -39.7% |
| FY2021 | 2021-12-31 | 3.05M | — |
Total Non-current Liabilities vs competitors
How CMPX compares with its peers on the latest reported figures
- CMPX's Mar 2026 total non-current liabilities of $8.42M is the 8th highest of the 11 companies compared; the peer median is $39.79M.
- Its year-over-year change of +34.2% is the highest of 9, against a peer median of -16.5%.
- Total non-current liabilities amounts to 4.1% of total assets for CMPX, versus a peer median of 14.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $290.06M | -20.6% | -0.0% | 101.4% | |
| Dec 2025 | $280.73M | — | — | 83.7% | |
| Mar 2026 | $233.88M | -2.0% | +3.1% | 181.4% | |
| Mar 2026 | $56.07M | -12.3% | +1.6% | 20.9% | |
| Mar 2026 | $49.19M | -42.8% | -16.3% | 7.5% | |
| Mar 2026 | $30.39M | -4.0% | +74.7% | 53.4% | |
| Mar 2026 | $17.67M | -7.5% | +4.9% | 3.4% | |
| Mar 2026 | $8.42M | +34.2% | +68.7% | 4.1% | |
| Mar 2026 | $3.6M | -40.6% | -27.3% | 1.0% | |
| Mar 2026 | $406K | -51.3% | -27.0% | 0.2% | |
| Mar 2026 | $131.57K | — | +164.1% | 0.1% | |
| Peer median (excluding CMPX) | $39.79M | -16.5% | +1.6% | 14.2% | |
Competitors are the stored peer set for CMPX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 144.51M | 34.95M | 24.23M | 43.48M | 30.64M |
| Short-term Investments | 0 | 151.66M | 128.23M | 83.24M | 178.26M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 8.18M | 1.42M | 6.03M | 913K |
| Total Current Assets | 147.11M | 194.79M | 153.88M | 132.75M | 209.82M |
| Property, Plant & Equipment (Net) | 6.33M | 4.53M | 2.67M | 7.08M | 9.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 320K | 320K | 320K | 568K | 568K |
| Total Non-current Assets | 6.65M | 4.85M | 2.99M | 7.65M | 9.77M |
| Total Assets | 153.76M | 199.65M | 156.88M | 140.4M | 219.59M |
| Account Payables | 867K | 3.38M | 4.09M | 2.25M | 1.59M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.6M | 1.56M | 1.94M | 2.79M | 2.68M |
| Total Current Liabilities | 10.63M | 16.17M | 7.8M | 8.87M | 13.97M |
| Long-term Debt | 0 | 0 | 0 | 0 | 8.83M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 1K | 0 |
| Total Non-current Liabilities | 3.05M | 1.84M | 536K | 6.3M | 8.83M |
| Total Liabilities | 13.68M | 18.01M | 8.34M | 15.17M | 22.8M |
| Common Stock | 10K | 13K | 13K | 13K | 18K |
| Retained Earnings | (233.59M) | (272.81M) | (315.31M) | (364.68M) | (431.17M) |
| Accumulated OCI | 0 | (302K) | 37K | 210K | 280K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 140.08M | 181.64M | 148.54M | 125.23M | 196.79M |
| Total Debt | 4.04M | 2.94M | 1.73M | 6.63M | 9.83M |
| Net Debt | (140.48M) | (32.01M) | (22.5M) | (36.85M) | (20.81M) |
Compass Therapeutics, Inc.
NASDAQ:CMPX
Intrinsic Alpha fair value
Locked
Current Price
$0.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.